Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRF1 | P14222 | 2/20 | 0.65 |
| ▸ | ACHE | P22303 | 1/20 | 0.65 |
| ▸ | KCNJ1 | P48048 | 7/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | MAOA | P21397 | 5/20 | 0.51 |
| ▸ | MAOB | P27338 | 5/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29861325 | 1.00 | PRF1 (0.65) | PRF1ACHEKCNJ1KCNH2MAPT | |
| SCHEMBL286654 | 0.86 | KCNJ1 (0.66) | PRF1ACHEKCNJ1KCNH2MAPT | |
| SCHEMBL1638547 | 0.86 | PRF1 (0.54) | PRF1ACHEMAOAMAOB | |
| SCHEMBL6104061 | 0.83 | KCNJ1 (0.62) | PRF1ACHEKCNJ1KCNH2MAPT | |
| SCHEMBL13554892 | 0.82 | KCNJ1 (0.60) | PRF1ACHEKCNJ1KCNH2MAPT | |
| SCHEMBL13870507 | 0.82 | KCNJ1 (0.60) | PRF1ACHEKCNJ1KCNH2MAPT | |
| SCHEMBL31135367 | 0.82 | KCNJ1 (0.60) | PRF1ACHEKCNJ1KCNH2MAPT | |
| SCHEMBL2733059 | 0.81 | AKR1B1 (0.62) | PRF1ACHEKCNJ1KCNH2MAPT | |
| SCHEMBL2724252 | 0.81 | KCNJ1 (0.59) | PRF1ACHEKCNJ1KCNH2MAPT | |
| SCHEMBL2731064 | 0.80 | KCNJ1 (0.55) | PRF1ACHEKCNJ1KCNH2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12180197-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| WO-2024222614-A1 | HETEROCYCLIC GSPT1 DEGRADATION AGENT | 北京诺诚健华医药科技有限公司 | 2024-10-31 | — | — | WO | disclosed |
| EP-4304712-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20220306614-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-09-29 | — | — | US | disclosed |
| US-10144746-B2 | Bridged bicyclic kallikrein inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-20180194780-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9815853-B2 | Bridged bicyclic kallikrein inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| WO-2016201052-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| US-20160362427-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2016-12-15 | — | — | US | disclosed |
| US-8597631-B2 | Linear self-eliminating oligomers | KTB TUMORFORSCHUNGSGESELLSCHAFT MBH (DE) | 2013-12-03 | — | — | US | disclosed |
| EP-1362856-B1 | WATER-SOLUBLE TRIAZOLE FUNGICIDE | DAIICHI SANKYO CO LTD (JP) | 2008-09-10 | — | — | EP | disclosed |
| EP-1362856-B1 | WATER-SOLUBLE TRIAZOLE FUNGICIDE | DAIICHI SANKYO CO LTD (JP) | 2008-09-10 | — | — | EP | disclosed |
| CN-100349569-C | Water-soluble triazole fungicide | SANKYO CO (JP) | 2007-11-21 | — | — | CN | disclosed |
| US-7230023-B2 | Water-soluble triazole fungicide | SANKYO COMPANY, LIMITED (JP) | 2007-06-12 | — | — | US | disclosed |
| US-7230023-B2 | Water-soluble triazole fungicide | SANKYO COMPANY, LIMITED (JP) | 2007-06-12 | — | — | US | disclosed |
| US-7230023-B2 | Water-soluble triazole fungicide | SANKYO COMPANY, LIMITED (JP) | 2007-06-12 | — | — | US | disclosed |
| CN-1720913-A | Water-soluble triazole fungicide | SANKYO CO (JP) | 2006-01-18 | — | — | CN | disclosed |
| US-20040198790-A1 | Water-soluble triazole fungicide | SANKYO COMPANY, LIMITED (JP) | 2004-10-07 | — | — | US | disclosed |
| CN-1503795-A | Water-soluble triazole antifungal agents | ������������ʽ���� | 2004-06-09 | — | — | CN | disclosed |
| EP-1362856-A1 | WATER-SOLUBLE TRIAZOLE FUNGICIDE | Sankyo Company, Limited (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220306614-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | PRF1 4754/4885ACHE 2532/4885KCNJ1 1746/4885 |
| US-10144746-B2 | Bridged bicyclic kallikrein inhibitors | KLKB1, KLK1, KLK2 | PRF1 1319/4885ACHE 1099/4885KCNJ1 664/4885 |
| US-20160362427-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK2 | PRF1 1319/4885ACHE 1099/4885KCNJ1 664/4885 |
| US-20180194780-A1 | BRIDGED BICYCLIC KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK2 | PRF1 1319/4885ACHE 1099/4885KCNJ1 664/4885 |
| US-20040198790-A1 | Water-soluble triazole fungicide | ERG28, CYP51A1, XDH | PRF1 269/4885ACHE 4062/4885KCNJ1 897/4885 |
| US-12180197-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | PRF1 4754/4885ACHE 2532/4885KCNJ1 1746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.